Adios, iTeos: Biotech folds weeks after GSK TIGIT termination
iTeos Therapeutics is throwing in the towel. Two weeks after axing its GSK-partnered TIGIT candidate, the biotech has decided to wind down operations, sell its assets and return as much of its $600 million-plus cash pile to investors as possible.
iTeos Therapeutics is throwing in the towel. Two weeks after axing its GSK-partnered TIGIT candidate, the biotech has decided to wind down operations, sell its assets and return as much of its $600 million-plus cash pile to investors as possible.
